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Prospective validation of a risk prediction model to identify high-risk patients for 
medication errors at hospital admission 
 
Abstract  
Background 
Pharmacy led medication reconciliation in elective surgery patients is often performed at 
the preoperative screening (POS). Because of the time lag between POS and 
admission, changes in medication may lead to medication errors at admission (MEA). In 
a previous study, a risk prediction model for MEA was developed.  
Objective 
To validate this risk prediction model to identify patients at risk for MEA in a university 
hospital setting.  
Methods 
The risk prediction model was derived from a cohort of a Dutch general hospital and 
validated within a comparable cohort from a Dutch University Medical Centre. MEA were 
assessed by comparing the POS medication list with the reconciled medication list at 
hospital admission. This was considered the gold standard. For every patient a risk 
score using the risk prediction model was calculated and compared with the gold 
standard. The risk prediction model was assessed with receiver operating characteristic 
(ROC) analysis. 
Results  
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Of 368 included patients, 167 (45.4%) had at least one MEA. ROC analysis revealed 
significant differences in the area under the curve of 0.535 (p=0.26) (validation cohort) 
versus 0.752 (p<0.0001) (derivation cohort). The sensitivity in this validating cohort was 
66% with a specificity of 40%.  
Conclusion and Relevance 
The risk prediction model developed in a general hospital population is not suitable to 
identify patients at risk for MEA in a university hospital population. However, number of 
medications is a common risk factor in both patient populations and should thus form the 
basis of an adapted risk prediction model.   
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Introduction 
Medication errors at admission (MEA) occur frequently and have potential clinical 
relevance.1,2 To reduce these MEA, medication reconciliation implementation in hospital 
transitions is recommended by the World Health Organization and the Joint 
Commission.3,4 The WHO describes medication reconciliation as “the formal process in 
which health care professionals’ partner with patients to ensure accurate and complete 
medication information transfer at interfaces of care”.3 Pharmacy-led medication 
reconciliation, which is considered the most cost-effective intervention5, can lead to a 
66% reduction in medication errors.6 In the Dutch guideline on prevention of MEA, 
medication reconciliation is required within 24 hours of admission.7 In patients who will 
undergo elective surgery, medication reconciliation is often part of the preoperative 
screening (POS).8 However, the time window between the POS and admission is 
usually larger than 24 hours.9 Therefore, medication reconciliation should be repeated at 
admission to comply with the guideline. 
To be able to select patients at high risk for MEA, risk factors need to be investigated. 
Hias et al.10 showed in a review that number of preadmission drugs and age have a 
predictive value for discrepancies. They advise to validate these variables in risk 
prediction models.  
In agreement with the results of the above mentioned review, we identified the number 
of medications in an earlier study in a general hospital as a potential risk factor for 
discrepancies. In addition, respiratory comorbidity was identified as a potential risk factor 
for patients with MEA after medication reconciliation at the POS in a multivariate logistic 
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model. Cardiovascular comorbidity was only significant in the univariate analysis.9 From 
the data of this study, a risk prediction model was constructed, containing these three 
variables. Although in this study the time between POS and admission was not identified 
as a potential risk factor, in 67% of the patients no difference in medication between 
POS and admission was found. Therefore, if patients at risk can be selected this could 
prevent a second interview in these patients. The ultimate aim is to use such a risk 
prediction model to identify patients at risk for MEA in all types of hospital settings, and 
to perform the second pharmacy-led medication reconciliation at admission in these 
patients at risk for an MEA only. This would result in a more efficient process, reducing 
workload for the clinical pharmacy and preventing redundant questions for patients at 
admission. To our knowledge there are no earlier studies that investigated a risk-
prediction model to select patients at high-risk for medication errors.  
To validate if the risk prediction model developed in the general hospital patient 
population can predict medication errors at admission correctly in a university hospital 
population, we performed this study. The secondary objectives are to identify potential 
additional risk factors for MEA in a university medical patient population and to evaluate 
the characteristics of these MEA. 
 
Methods 
Study design 
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For the derivation cohort we used an observational quantitative study design, in which 
medication discrepancies were identified by comparing the preoperatively screened 
medication with the medication at hospital admission. 
For the validation cohort the same study design was used to retrieve the gold standard 
data. In addition, for each patient the outcome of the risk prediction model was 
calculated and compared to the gold standard. 
Derivation cohort 
The risk prediction model that was validated in this study was derived from a general 
hospital setting (Zaans Medical Centre, Zaandam, The Netherlands). The Zaans Medical 
Centre is a 300 bed general hospital with around 12,500 clinical admissions every year. 
Patients were included at the POS when given informed consent, were 18 years or 
older, and admitted to hospital for at least 24 hours.  Exclusion criteria were patient or 
accompanying caregiver was not able to participate in the medication reconciliation, or  
a patient received additional pre-surgery medication reconciliation by the admitting 
medical ward. Patients were included between October 26 and December 18, 2015. The 
primary outcome was the proportion of patients with one or more MEA.9 Medication 
reconciliation consisted of a standardized medication interview with the patient 
performed by a researcher (pharmacist or pharmacist in training). The researcher was 
trained to work according to the medication reconciliation method used by the pharmacy 
technicians at the POS. When available, a recently obtained community pharmacy 
record, a medication list brought by the patient and/or his medication boxes were used 
to verify actual medication use with the patient. In case the patient could not answer 
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these questions completely, the accompanying caregiver was interviewed as well. 
Medication reconciliation took place either pre- or post-operatively. Discrepancies 
between medications at the POS and medications at admission were divided into 
intentional and unintentional discrepancies using the patient medical record and if 
necessary information from the attending physician. Discrepancies were seen as 
intentional if home medication was intentionally altered during admission. Unintentional 
discrepancies are defined as home medication that was not correct in the electronic 
record and confirmed by a physician that it was unintentional. Unintentional medication 
discrepancies between the hospital electronic medical record and the actual used 
medication were defined as medication errors at admission (MEA). When an MEA was 
found, this was communicated with and corrected by the attending physician.  
Validation cohort 
The validation cohort was derived from patients admitted for elective surgery in a 
university hospital setting and performed at the Leiden University Medical Centre 
(LUMC) in The Netherlands. The LUMC is a 800 bed university hospital with around 
25,000 clinical admissions every year.  The study received a waiver from the Medical 
Ethics Committee of the LUMC, as it complied with the Medical Research in Humans 
Act. Patients were included between October 17, 2016 and August 29, 2017. The data 
was prospectively collected using the same methods as in the derivation cohort.  
Outcome 
The primary outcome was the proportion of patients with one or more MEA. This 
outcome was used as the gold standard, to which the outcome predicted by the risk 
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prediction model was compared. Sensitivity and specificity, were reported. The area 
under the curve (AUC) of the receiving operating characteristics (ROC) curves from the 
derivation cohort9 and the validation cohort were compared. Secondary outcomes were 
potential risk factors for MEA in the validation cohort, type and severity of the MEA as 
well as the type of medications involved in the MEA. 
Candidate predictors 
The following patient characteristics were collected in the validation cohort as candidate 
predictors of MEA: age, sex, time in days between preoperative screening and 
admission, number of medications at the POS and admission, level of education, 
presence of comorbidities (cardiovascular disease, hypertension, respiratory disease, 
cerebrovascular accident, kidney disorder, thrombosis/embolism, diabetes mellitus, 
thyroid disorder), ward type and medical specialty. In the medication reconciliation 
interview the number of medications and the level of education (primary school, 
secondary school, high school, vocational education, university of applied sciences or 
university) was determined.  
Classification of medication errors and medication types 
The MEA were classified by error type and severity. Three types of medication errors 
were defined: omission (not in the hospital record, but observed to be in use), 
commission (in the hospital record, but not observed to be in use) and frequency/dose 
(medication in the hospital record, but in another frequency or dose than observed). The 
severity of the MEA was classified using the NCC MERP medical error index (Figure 
1).11 Category A and B were not included as medication errors in this study, because 
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these are categories that did not reach the patient. Therefore MEA were classified in 
category C to I. The identified MEA were assessed with respect to NCC MERP severity 
class by two hospital pharmacists (KG and ME) independently from each other. In case 
their assessments differed, they met to reach consensus. Anatomic Therapeutic 
Chemical (ATC) code of medications involved in MEA was noted, to evaluate which 
medication subclass was more involved in MEA.12  
Risk prediction model 
The risk prediction model, that was developed from the data of the derivation cohort9, 
was: Risk score = 0.152 * N + 0.907 * C + 1.446 * R. In which N = number of 
medications at POS, C = cardiovascular comorbidity, and R = respiratory comorbidity. 
Other patient characteristics did not remain significant in the multivariate risk prediction 
model. From the ROC curve of this development cohort the risk score of 0.5 was chosen 
as cut-off with a sensitivity of 70% and specificity of 62%. For every patient from the 
validation cohort the risk score was calculated using this risk prediction model. Every 
patient with a risk score above 0.5 was defined as a patient at risk for MEA.  
Model validation 
The required sample size for the validation cohort was estimated at 162 patients with an 
MEA, using the sensitivity of 70%, alpha of 0.025 and beta of 0.20 and a sensitivity of 
60% or higher as equivalent proportion. Based on an estimated prevalence of 33%9, a 
sample size of 500 patients was calculated. The study protocol included an interim 
analysis after 300 patients to evaluate the prevalence of MEA and if necessary to adjust 
the sample size. The data were transferred from OpenClinica version 3.8 (OpenClinica 
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LLC, Waltham, USA) to SPSS Statistics version 23 (IBM Corp, Armonk, NY) for 
analysis.  
The proportion of patients with MEA was calculated dividing the patients with MEA by 
the total number of included patients. For every patient the actual occurrence of MEA 
was compared to the predicted occurrence of MEA. The diagnostic value of the 
prediction model was established by calculating the sensitivity and specificity. The ROC 
curves of the risk prediction model and these validation parameters were compared to 
establish the fit of the model.  
Secondly, the association of all potential risk factors with the occurrence of MEA was 
analysed using univariate logistic regression. If the p-value was < 0.20, the parameter 
was analysed in a stepwise backwards multivariate logistic regression model and was 
retained in the model if it changed the beta coefficient with more than 10%. Odds ratio’s 
(OR) and 95% confidence intervals (95% CI) were reported.  
Type and severity of MEA and type of medication was analysed using descriptive 
statistics. 
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Results 
After screening of 1005 patients, 368 patients were included according to the study flow 
in Figure 2. The most common cause for exclusion was the availability of patients for the 
interview (59%). Of these non-available patients 152 (24%) were not included due to 
transfer to a medical ward where the study was not executed. Another 10% was due to 
the patient being asleep at the time the researcher arrived and 10% due to other medical 
staff that was with the patient.  
Table 1 shows the general characteristics of the included patients of the validation 
cohort and derivation cohort. The mean age of the validation population was 61.3 years 
with a standard deviation (SD) of 13.6 compared to 61.8 with SD 16.3 in the derivation 
population. Men (52%) and women (48%) were included almost equally in the validation 
cohort, compared to 42% male and 58% female in the derivation cohort. On average a 
lag of 27.8 days existed between the POS and admission with a large variation (SD 31.6 
days) compared to 32.8 ± 24.8 days in the derivation cohort. On average, patients used 
4.7 medications (SD 4.2) at the POS in the validation cohort significantly more than the 
average of 3.7 medications (SD 3.5) in the derivation cohort. Furthermore the population 
of the derivation cohort significantly differed in level of education, and occurrence of 
cardiovascular disease, kidney disorder, and thrombosis/embolism.  
Of the 368 patients included, 167 (45.4%) had at least one MEA. For 8 patients the risk 
score could not be calculated because the cardiovascular comorbidity was unknown. For 
360 patients the prediction of MEA using the risk prediction model is compared to the 
actual occurrence of MEA. This resulted in 108 patients with MEA that were correctly 
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predicted to have MEA and 79 patient without MEA that were correctly predicted to 
having no MEA. 56 patients had MEA but it was predicted they would not have MEA and 
117 patients had no MEA but were predicted to have MEA. The sensitivity in this 
validating cohort is 66%, with a  specificity of 40%.  The sensitivity of the derivation 
cohort is 70% with a specificity of 62%. The ROC curves of the prediction model in the 
derivation and validation cohort are shown in figure 3. The AUC of the validation cohort 
is 0.535 (p = 0.26). This means only half of the MEA is predicted correctly by this model 
and this is not significantly better than chance. The AUC of the ROC curve of the 
derivation cohort is 0.752 (p <0.0001). This means about 75% of the MEA are correctly 
predicted by this model and this is significantly better than chance.  
In Table 2 the results of the univariate logistic regression analysis are presented. Only 
the number of medications at admission OR 1.06 (95% CI 1.01-1.12) was significantly 
associated with the occurrence of MEA. In the stepwise backwards multivariate logistic 
regression, the two potential risk factors that showed a p-value below 0.20 in the 
univariate analysis were analysed. None of the variables remained in the equation and 
therefore the results of the univariate analysis are the final results for the associated 
potential risk factors. No additional risk factors were identified.  
In the 167 patients with at least one MEA, 302 MEA were found. Of these MEA 145 
(48%) were omissions, 90 (30%) were commissions and 67 (22%) consisted of changes 
in dose/frequency. 193 (63%) of the MEA in 133 (36%) patients, were classified to at 
least have the potential to be harmful (NCC MERP category D, E or F). Medications of 
the ‘Alimentary tract and metabolism’ (26%) ATC class were most frequently involved in 
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MEA, followed by ‘Nervous system’ (18%), ‘Dermatologic’ (12%) and ‘Respiratory 
medication’ (11%).   
Discussion 
This study showed that the risk prediction model developed with data from the derivation 
cohort9 is not suitable to predict MEA in patients in the validation cohort. In this study 
45.4% of included patients had at least one MEA. This is substantially higher than the 
results of earlier studies6,13 and 12% higher than the derivation cohort9. This could be 
explained by the more complex patient population in the university hospital setting from 
the validation cohort. Cardiovascular comorbidity occurred almost twice as often (21% 
versus 10%) and kidney disorder and thrombosis occurred more than twice as often in 
the validation cohort (respectively 8% versus 3%; 9% versus 2%). Furthermore, more 
patients (36% vs 9%) had a potentially harmful MEA in the validation cohort. This 
confirms the more complex patient population in the university hospital setting.  
The higher percentage can also be explained by the higher number of medications used 
(average 4.7 compared to 3.7). In the logistic regression number of medications at the 
POS is significantly associated with the occurrence of MEA. This corresponds with the 
findings of earlier studies.8,10   
Compared to the derivation cohort more omissions were found, comparable with earlier 
studies.1,13 The ATC medication classes most frequently involved in MEA were the same 
as in the derivation cohort. The medication classes ‘Alimentary tract and metabolism’, 
‘Nervous system’, ‘Dermatologic’, and ‘Respiratory medication’ should get more 
attention in the medication reconciliation process. Unfortunately the medication class is 
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not suitable as a risk factor to predict MEA because most MEA are omissions and 
therefore the medication class is not known at the moment of risk assessment.  
This is the first validation study of a risk prediction model for patients at risk for MEA. A 
strength of this study is that it included patients of all surgical specialties and therefore 
the findings are representative for daily clinical practice. The number of medications is 
represented in the risk prediction model and is an independent risk factor associated 
with MEA in the validation cohort as well, confirming the importance of this potential risk 
factor. Another strength of this study is that the derivation cohort and validation cohort 
are studied applying the same study procedures.  
Some limitations need to be discussed. First of all more than half of the eligible patients 
are not included in the validation cohort. This is explained by the fact that patients who 
undergo surgery are often not in their hospital bed due to the surgery itself but also 
because of different appointments to help recover after surgery. However, we do not 
expect this to result in selection bias, as these logistic reasons apply to all patients. In 
February 2017 the gynaecology department of the LUMC introduced an intervention to 
perform a second medication reconciliation for every patient in the week before 
admission. Therefore when this intervention started the gynaecology department was 
excluded in this study. This means that only during half of the inclusion time of the 
validation cohort, patients of this specialty could participate in the study. However, we do 
not believe this affected the results because no difference has been demonstrated 
between the medical specialties. Another limitation of this study is that differences in 
medication overview after medication reconciliation can be caused by different 
approaches of the interview instead of actual changes in medication between the two 
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medication reconciliation moments. Patients could forget to mention a medicine at the 
POS and remember it again at admission. We tried to minimize this risk by performing 
both medication reconciliation interviews according to the same protocol. However, we 
did not ask the patients when medication changes were discovered, where these 
changes originated from.  
Future research is necessary to be able to identify high-risk patients with a better 
specificity and sensitivity. For the time being it is advised to perform a second 
medication reconciliation in elective patients at admission because 45% of patients still 
have MEA. To prevent the unnecessary performance of medication reconciliation in 
more than half of the patients better prediction models are necessary to select patients 
at high risk for an MEA. Future research that combines data from different patient 
populations would be helpful to establish this.  
Conclusion and Relevance 
The risk prediction model developed in a general hospital patient population is not 
suitable to identify patients at risk of medication errors at admission (MEA) in a 
university hospital patient population. This may be due to the more complex patients in 
the university hospital patient population. The number of medications is a common risk 
factor in both patient populations and should thus form the basis of an adapted risk 
prediction model.  
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Figure 1 NCC MERP index for categorizing medication errors 
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Figure 2 Study flow 
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Table 1 Patient characteristics for validation cohort (n=368) and derivation cohort (n=183) 
 Validation 
cohort 
Derivation 
cohort 
p-value 
Age, mean ± SD 61.3 ± 13.6  61.8 ± 16.3 0.704 
Sex (female), N (%) 176 (48%) 106 (58%) 0.199 
Days between POS and admission, 
mean ± SD 
27.8 ± 31.6  32.8 ± 24.8 0.062 
Number of medications at POS, mean ± 
SD 
4.7 ± 4.2 3.7 ± 3.5 0.006* 
Number of medications at admission, 
mean ± SD 
4.8 ± 4.0 3.6 ± 3.5 0.001* 
Level of education, N (%) 
- Primary school 
- Secondary school 
- High school 
- Vocational education 
- Univeristy of applied sciences 
- University 
- Unknown 
 
35 (10%) 
72 (20%) 
25 (7%) 
98 (27%) 
69 (19%) 
43 (12%) 
26 (7%) 
 
14 (8%) 
43 (23%) 
9 (5%) 
72 (39%) 
35 (19%) 
10 (5%) 
- 
0.029* 
 
Comorbidities, N (%) 
Cardiovascular disease 
Hypertension 
Respiratory disease 
Cerebrovascular accident  
Kidney disorder 
Thrombosis/embolism 
Diabetes mellitus 
Thyroid disorder 
 
75 (21%) 
136 (37%) 
45 (12%) 
17 (5%) 
30 (8%) 
32 (9%) 
46 (13%) 
27 (7%) 
 
22 (12%) 
55 (30%) 
22 (12%) 
10 (5%) 
6 (3%) 
4 (2%) 
19 (10%) 
17 (9%) 
 
0.012* 
0.104 
0.946 
0.835 
0.020* 
0.003* 
0.390 
0.486 
Abbreviations: POS = preoperative screening, SD = standard deviation,  
*p<0.05  
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Figure 3 Receiving Operater Characteristic curves of the prediction model in the derivation vs 
the validation cohort 
 
Receiving Operator Characteristics curves; the curved line is the prediction of a medication error 
at admission (MEA) vs the real occurrence of MEA. The straight line is the reference. On the left: 
derivation cohort, the area under the curve (AUC) is 0.752 p-value <.0001. On the right: 
validation cohort, the AUC is 0.535 p-value 0.26. 
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Table 2 Univariate logistic regression of patient factors associated with medication errors at 
admission 
Parameter Odds Ratio (95%-
confidence interval) 
Age 0.92 (0.98-1.01) 
Sex 0.92 (0.61-1.39) 
Number of medications at preoperative screening 1.06 (1.01-1.12)* 
Time in days between preoperative screening and 
admission 
1.00 (0.99-1.01) 
Level of education1 
Secondary school 
High school 
Vocational education 
University of applied sciences 
University 
 
1.59 (0.70-3.60) 
2.14 (0.70-6.97) 
0.90 (0.18-4.38) 
1.03 (0.47-2.27) 
0.91 (0.39-2.09) 
Comorbidities  
Cardiovascular disease 
Hypertension 
Respiratory disease 
Cerebrovascular accident (CVA) 
Kidney disorder 
Thrombosis/embolism 
Diabetes mellitus 
Thyroid disorder 
 
0.94 (0.56-1.56) 
1.07 (0.70-1.63) 
1.58 (0.84-2.96)** 
1.37 (0.52-3.64) 
1.23 (0.58-2.61) 
1.59 (0.77-3.31) 
0.76 (0.40-1.43) 
1.33 (0.61-2.92) 
1Primary school is the reference level 
*p-value < 0.05 
**p-value < 0.20 
 
 
 
